Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?

J Viral Hepat. 2023 Oct;30(10):790-792. doi: 10.1111/jvh.13868. Epub 2023 Jul 4.

Abstract

Hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma and mortality among people living with HIV (PLWH). HBV vaccination provides protection from infection; however, vaccination rates are low. We conducted a retrospective analysis at three HIV centres in Texas to determine the proportion of PLWH who received the recommended 3 doses of hepatitis B vaccine within 1 year. Factors associated with vaccination completion were explored. In our sample of three sites in a state with high HIV transmission and high rates of liver disease from 2011 to 2021, showed low rates of hepatitis B vaccination. Among eligible PLWH, only 9% completed the 3-dose hepatitis B vaccine series in 1 year. There is an urgent need to improve HBV vaccination to reach 2030 target for hepatitis B elimination.

Keywords: HIV; hepatitis B vaccination; practice patterns.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • HIV Infections* / complications
  • HIV Infections* / epidemiology
  • Hepatitis B Vaccines
  • Hepatitis B virus
  • Hepatitis B* / epidemiology
  • Hepatitis B* / prevention & control
  • Humans
  • Liver Neoplasms* / complications
  • Prevalence
  • Retrospective Studies
  • Vaccination

Substances

  • Hepatitis B Vaccines